About FBDIX
Franklin Biotechnology Discovery Fund Class A is an open-end mutual fund focused on **capital appreciation through investments in the biotechnology sector**. Its core mandate is to allocate at least 80% of its net assets to equity securities of biotechnology companies and discovery research firms, which may include organizations involved in drug discovery, genomics, genetic engineering, and gene therapy. The fund's holdings span both established large-cap biotechnology firms and emerging companies, offering balanced exposure across different stages of the industry lifecycle. Notable positions typically include leaders in healthcare innovation, such as Amgen, Regeneron Pharmaceuticals, and Vertex Pharmaceuticals. The fund’s investment universe also extends to companies involved in applying biotechnology advances to healthcare, pharmaceuticals, and, to a lesser extent, agriculture. As a non-diversified fund, it generally holds a concentrated portfolio, often allocating a substantial portion of assets to its top ten holdings. With a specialization in a fast-evolving and research-driven field, Franklin Biotechnology Discovery Fund Class A plays a distinct role in the market by channeling capital to firms at the forefront of medical and scientific progress, appealing to investors seeking targeted exposure to the biotechnology sector.
Fund Family Franklin Templeton Investments
Category Health
Stock Exchange NASDAQ
Ticker Symbol FBDIX
Share Class Class A
Index NASDAQ Biotechnology CR
FBDIX had a total return of 1.23% in the past year, including dividends. Since the fund's
inception, the average annual return has been 9.49%.
